At 96 weeks, both RAL and Control maintained efficacy greater than 75% and continued to demonstrate similar safety profiles.
Lopinavir/ritonavir (LPV/r) and raltegravir (RAL)
LPV/r with nucleoside/nucleotide reverse transcriptase inhibitors (Control)
VL <200 copies/mL at 96 weeks